PTC Therapeutics CLO sells 3,019 company shares

PTC Therapeutics executive Mark Elliott Boulding, Executive VP and Chief Legal Officer, reported open-market sales of a total of 3,019 shares of common stock on February 19, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

PTC Therapeutics executive Mark Elliott Boulding, Executive VP and Chief Legal Officer, reported open-market sales of a total of 3,019 shares of common stock on February 19, 2026. The transactions, executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 4, 2024, occurred at weighted-average prices of $68.54 and $69.82 per share, based on multiple trades within disclosed price ranges from $67.99 to $70.18. Following these sales, Boulding directly held 105,212 shares of PTC Therapeutics common stock.

Insider Trade Summary

Net Seller: 3,019 shares

Net Sell 4 txns

Insider Boulding Mark Elliott

Role EXEC. VP AND CLO

Sold 3,019 shs ($210K)

Type	Security	Shares	Price	Value
Sale	Common Stock	588	$68.54	$40K
Sale	Common Stock	1,629	$69.82	$114K
Sale	Common Stock	212	$68.54	$15K
Sale	Common Stock	590	$69.82	$41K

Holdings After Transaction: Common Stock — 105,212 shares (Direct)

Footnotes (3)

F1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.
F2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $67.99 to $68.93 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $69.52 to $70.18 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PTC Therapeutics (PTCT) report for Mark Elliott Boulding?

PTC Therapeutics reported that Executive VP and Chief Legal Officer Mark Elliott Boulding sold 3,019 shares of common stock on February 19, 2026, in open-market transactions under a Rule 10b5-1 trading plan, at weighted-average prices of $68.54 and $69.82 per share.

How many PTC Therapeutics (PTCT) shares did Mark Elliott Boulding sell and at what prices?

Mark Elliott Boulding sold a total of 3,019 PTC Therapeutics common shares in four open-market transactions at weighted-average sale prices of $68.54 and $69.82 per share, reflecting multiple trades within disclosed intraday price ranges between $67.99 and $70.18 per share.

Does the PTC Therapeutics (PTCT) Form 4 use a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were executed under a written Rule 10b5-1 trading plan adopted by Mark Elliott Boulding on December 4, 2024, indicating the sale instructions were pre-established rather than being made on a discretionary, same-day trading decision basis.

How many PTC Therapeutics (PTCT) shares does Mark Elliott Boulding hold after the reported sales?

After completing the reported open-market sales, Mark Elliott Boulding directly holds 105,212 shares of PTC Therapeutics common stock, as shown by the final ownership figure reported following the last transaction dated February 19, 2026, in the Form 4 filing.

What role does Mark Elliott Boulding hold at PTC Therapeutics (PTCT)?

Mark Elliott Boulding is identified as Executive Vice President and Chief Legal Officer of PTC Therapeutics. His status as an officer makes him a reporting person subject to Form 4 disclosure requirements for changes in his beneficial ownership of the company’s common stock.

Were PTC Therapeutics (PTCT) insider sales executed in multiple trades on the transaction date?

Yes. The Form 4 notes that the weighted-average prices reflect multiple sale transactions executed within price ranges of $67.99 to $68.93 and $69.52 to $70.18 per share, with further breakdowns available upon request to the company, the SEC staff, or security holders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/23/2026 - 05:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boulding Mark Elliott

(Last)

(First)

(Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN

07059

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EXEC. VP AND CLO

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/19/2026		S⁽¹⁾		588	D	$68.54⁽²⁾	107,643	D
Common Stock	02/19/2026		S⁽¹⁾		1,629	D	$69.82⁽³⁾	106,014	D
Common Stock	02/19/2026		S⁽¹⁾		212	D	$68.54⁽²⁾	105,802	D
Common Stock	02/19/2026		S⁽¹⁾		590	D	$69.82⁽³⁾	105,212	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $67.99 to $68.93 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $69.52 to $70.18 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

	/s/ Avraham S. Adler, Attorney-in-Fact	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR